Can You Take Repatha (Evolocumab) with Pregabalin?

Why This Combination Comes Up Clinically

Patients with atherosclerotic cardiovascular disease (ASCVD) frequently manage comorbid neuropathic pain conditions. Pregabalin carries FDA approval for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury pain [1]. Evolocumab is prescribed for heterozygous or homozygous familial hypercholesterolemia (FH) and established ASCVD when statins alone do not reach LDL-C targets [2].

Overlap in ASCVD and Neuropathy Populations

Roughly 50% of patients with diabetes develop some form of peripheral neuropathy over their lifetime, per a 2017 Diabetes Care position statement [3]. These same patients carry elevated cardiovascular risk. A 2019 retrospective cohort analysis (N=8,932) in JAMA Cardiology found that diabetic adults with neuropathy had a 1.6-fold higher rate of major adverse cardiovascular events compared to matched diabetic controls without neuropathy [4]. PCSK9 inhibitors are increasingly used in this population after the FOURIER trial (N=27,564) demonstrated that evolocumab reduced composite cardiovascular endpoints by 15% over a median of 2.2 years [5].

Why Patients Ask

Pregabalin is a Schedule V controlled substance with recognized abuse potential and central nervous system (CNS) depressant effects. Patients understandably want confirmation that adding a biologic lipid-lowering agent will not amplify sedation, dizziness, or muscle-related side effects. The short answer: it does not.

Pharmacokinetic Interaction Analysis

The risk of a drug-drug interaction (DDI) depends on shared metabolic pathways, transporter competition, and protein-binding displacement. Evolocumab and pregabalin share none of these.

Evolocumab Metabolism

Evolocumab is a fully human IgG2 monoclonal antibody. Like other large-molecule biologics, it undergoes proteolytic catabolism through the reticuloendothelial system and target-mediated drug disposition (TMDD) via PCSK9 binding [2]. It does not interact with cytochrome P450 isoenzymes (CYP1A2, 2C9, 2C19, 2D6, 3A4), P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or any other small-molecule transporter. The FDA-approved prescribing information for Repatha explicitly states: "No formal drug interaction studies have been performed. No interactions are expected based on the route of elimination" [2].

Pregabalin Metabolism

Pregabalin is a gabapentinoid anticonvulsant that undergoes negligible hepatic metabolism. Over 90% of the oral dose is excreted unchanged in urine, with a renal clearance of approximately 67 mL/min [1]. It has no CYP enzyme inhibition or induction activity. Protein binding is below 1%. The Lyrica prescribing information confirms that pregabalin "does not inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4" [1].

Net Pharmacokinetic Risk

A monoclonal antibody cleared by proteolysis and a small molecule cleared renally without CYP involvement occupy entirely separate pharmacokinetic compartments. No mechanism exists for one to alter the plasma concentration of the other. This assessment aligns with the Lexicomp, Micromedex, and Clinical Pharmacology databases, none of which flag an evolocumab-pregabalin interaction as of May 2026.

Pharmacodynamic Interaction Analysis

Even when pharmacokinetic pathways do not overlap, two drugs can produce additive or opposing pharmacodynamic (PD) effects on the same organ system. This section evaluates the relevant PD domains.

Musculoskeletal Effects

Evolocumab is associated with musculoskeletal pain in clinical trials. In FOURIER, arthralgia occurred in 3.3% of evolocumab patients vs. 3.0% on placebo, and myalgia in 3.3% vs. 3.0% [5]. These rates were not statistically different from placebo, but real-world postmarketing reports sometimes describe muscle-related complaints.

Pregabalin is not typically associated with myopathy. Weight gain (up to 7% of patients at doses above 300 mg/day) and peripheral edema (6% in pooled RCTs) are the notable somatic effects [1].

No overlapping PD mechanism amplifies musculoskeletal toxicity when these two drugs are combined.

CNS Depression

Pregabalin causes somnolence (15-25% incidence depending on dose) and dizziness (up to 38% at 600 mg/day in neuropathic pain trials) [1]. Evolocumab has no CNS depressant activity. It does not cross the blood-brain barrier in pharmacologically relevant concentrations. Combining the two drugs does not increase sedation risk beyond what pregabalin produces alone.

Hepatic and Metabolic Effects

Evolocumab lowers LDL-C by 59% on average (vs. Placebo) across phase III trials [6]. Pregabalin has no meaningful effect on lipid metabolism. There is no PD antagonism or combination on hepatic lipid handling.

Severity Rating Across Major DDI Databases

Drug interaction databases use tiered classification systems. For evolocumab plus pregabalin, the picture is consistent: no interaction flagged.

Database-by-Database Assessment

• Lexicomp: No interaction listed between evolocumab and pregabalin.
• Micromedex (IBM): No monograph pairing exists; the combination generates no alert.
• Clinical Pharmacology (Elsevier): No interaction record.
• FDA Adverse Event Reporting System (FAERS): No disproportionality signal for co-reported adverse events with the combination as of Q1 2026 [7].

How to Interpret "No Interaction Listed"

Absence of a listing in DDI databases is not the same as a proven negative. It means that, based on mechanistic pharmacology, clinical trial safety data, and postmarketing surveillance, no signal of harm has emerged. For a monoclonal antibody and a renally cleared gabapentinoid, this absence is pharmacologically expected, not merely a gap in evidence.

Monitoring Recommendations When Using Both Drugs

Standard monitoring protocols for each drug individually should be followed. No additional monitoring is required specifically because of their co-prescription.

For Evolocumab

The American College of Cardiology (ACC) and American Heart Association (AHA) 2018 cholesterol guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating a PCSK9 inhibitor and every 3 to 12 months thereafter [8]. Monitor for injection-site reactions (the most common adverse event at 5.7% in FOURIER) and nasopharyngitis [5].

For Pregabalin

Check renal function at baseline. The dose must be adjusted when creatinine clearance falls below 60 mL/min: 75 mg twice daily (CrCl 30-60 mL/min), 75 mg once daily (CrCl 15-30 mL/min), or 25-75 mg once daily (CrCl <15 mL/min) [1]. Monitor for weight gain, peripheral edema (especially in patients also taking thiazolidinediones), and CNS effects including suicidal ideation, per the class-wide FDA boxed warning for antiepileptic drugs [9].

Special Population: Diabetic Patients on Both Agents

In patients with type 2 diabetes who take evolocumab for ASCVD risk reduction and pregabalin for diabetic neuropathy, HbA1c monitoring every 3 months is already standard. Pregabalin can cause weight gain (mean +1.6 kg in 12-week trials at 300 mg/day), which may modestly worsen insulin resistance [1]. Evolocumab has no clinically meaningful effect on glycemic control, based on pooled safety data from over 6,000 patients with diabetes in the PCSK9 inhibitor trials [10].

Dose Adjustment Guidance

No dose modification of either drug is warranted when they are prescribed together.

Evolocumab Dosing Remains Standard

The standard regimens are 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly [2]. These doses are fixed; there is no titration protocol based on co-medications. The FDA label does not list any drug that requires evolocumab dose adjustment.

Pregabalin Dosing Remains Indication-Based

Pregabalin dosing varies by condition: 150 to 300 mg/day for diabetic neuropathy, up to 600 mg/day for postherpetic neuralgia, and 300 to 450 mg/day for fibromyalgia [1]. The only dose-modifying factor is renal impairment. Co-administration with evolocumab does not change these parameters.

Patient Counseling Points

What to Tell Patients

Explain that Repatha works through a completely different biological pathway than pregabalin. Repatha is a protein injected under the skin that lowers cholesterol by blocking PCSK9. Pregabalin is a small molecule taken orally that calms overactive nerve signals. The two drugs do not "see" each other in the body.

Timing of Administration

No specific spacing between doses is necessary. Patients can take their oral pregabalin at their usual time and administer the evolocumab injection on their regular biweekly or monthly schedule without regard to when the last pregabalin dose was taken.

When to Contact a Clinician

Patients should report unexplained, persistent muscle pain (to differentiate from statin-related myopathy if they are also on a statin), unusual swelling, severe dizziness, or signs of allergic reaction after the evolocumab injection (rash, urticaria, facial swelling). These are standard safety counseling points for each drug individually, not signals of a drug-drug interaction.

Statin Consideration: The Third Drug in the Room

Most patients on evolocumab are also on a statin. Statins are CYP3A4 substrates (atorvastatin, simvastatin, lovastatin) or CYP2C9 substrates (fluvastatin, rosuvastatin). Pregabalin does not inhibit any of these CYP enzymes [1], so it does not affect statin exposure either. The "triple combination" of a statin, evolocumab, and pregabalin introduces no additional interaction risk.

Real-World Polypharmacy Context

A 2022 cross-sectional analysis of Medicare Part D claims data (N=1.2 million beneficiaries with ASCVD) published in Circulation: Cardiovascular Quality and Outcomes found that 34% of PCSK9 inhibitor users were taking five or more concomitant medications [11]. Gabapentinoids ranked among the top 15 co-prescribed drug classes. No safety signal emerged from this large real-world dataset.

What About Other PCSK9 Inhibitors?

Alirocumab (Praluent) shares the same IgG monoclonal antibody pharmacokinetic profile and the same absence of CYP/transporter interactions [12]. Inclisiran (Leqvio), a small interfering RNA (siRNA) targeting PCSK9 mRNA in hepatocytes, is also not metabolized by CYP enzymes and is not expected to interact with pregabalin [13]. The entire PCSK9-inhibitor class, whether antibody- or siRNA-based, poses no DDI risk with gabapentinoids.

Patients prescribed 140 mg evolocumab every two weeks alongside pregabalin 150 to 600 mg daily require no interaction-specific monitoring, no dose changes, and no administration spacing beyond what each drug's label already recommends [1][2].